Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Arm spasticity after stroke: botulinum toxin therapy in combination with multimodal stimulation

https://doi.org/10.14412/2074-2711-2020-3-19-23

Full Text:

Abstract

Post-stroke spasticity (PS) occurs in most patients with stroke and contributes to the development of pain syndrome and contractures, which substantially impairs the restoration of lost motor functions (MFs) and the quality of life of the patient.

Objective: to evaluate the efficacy of a combination of botulinum toxin A (BTA) and multimodal stimulation in patients with arm PS.

Patients and methods. The investigation enrolled 84 patients aged 18 to 85 years with PS, who had experienced ischemic stroke (IS) 1 month to 1 year before. In the study group (n=56), complex rehabilitation treatment was preceded by the use of BTA, while in the control group (n=28), multimodal rehabilitation therapy was performed without using BTA. Before and after treatment, neurological deficit was evaluated using the modified Ashworth scale (MAS), the Fugl—Meyer (FM) assessment scale, the British muscle strength grading scale, the Action Research Arm Test (ARAT), the Barthel index, and the modified Rankin scale.

Results and discussion. According to MAS, there was a statistically significantly spasticity reduction after BTA use in the study group compared to the control one (median 1 [1; 2] and 2 [2; 3] scores, respectively; p=0.0003). According to the FM scale, an improvement in arm MFs was noted in the study group compared to the control one (median 29.5 [20; 42] and 21 [13.5; 31.5] scores, respectively; p=0.008) and according to the ARAT scale this was observed in the study and control groups (14.5 [7; 27] and 3 [0; 12] scores, respectively; p=0.0004).

In patients with upper limb PS, the use of BTA before a rehabilitation cycle using multimodal stimulation was shown to be statistically significantly more effective than the similar neurorehabilitation cycles without prior BTA therapy. The findings can be used in the routine practice of a neurologist when planning rehabilitation for more effective and well-founded treatment in patients with arm PS.

Conclusion. Incorporation of BTA into multimodal stimulation was ascertained to be effective in patients with PS. 

About the Authors

V. N. Lutsik
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation

Vasily Nikolaevich Lutsik.

61/2, Shchepkin St., Moscow 129110.



E. V. Slyunkova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation

61/2, Shchepkin St., Moscow 129110.



S. V. Kotov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation

61/2, Shchepkin St., Moscow 129110.



V. K. Misikov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation

61/2, Shchepkin St., Moscow 129110.



E. V. Biryukova
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences
Russian Federation

5A, Butlerov St., Moscow 117485.



References

1. Brainin M. Poststroke Spasticity: Treating to the disability. Neurology. 2013 Jan 15;80(3 Suppl 2): S1-4. doi: 10.1212/wnl.0b013e3182762379.

2. Klochikhina OA, Stakhovskaia LV. An analysis of epidemiological indices of stroke based on the data of a regional populationregister from 2009 to 2012. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;(6-1):63-9. (In Russ.).

3. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischemic stroke and transient ischemic attack. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.

4. Urban PP, Wolf T, Uebele M. Occurrence and ceruical predictors of spasticity after ischemic stroke. Stroke. 2010 Sep;41(9):2016-20. doi: 10.1161/STROKEAHA.110.581991. Epub 2010 Aug 12.

5. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009 Jan;41(1):13-25. doi: 10.2340/16501977-0303.

6. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957 May;2(5):200-15.

7. Mahoney FI, Barthel D. Functional evaluation: the Barthel Index. Md State Med J. 1965 Feb;14:61-5.

8. Fugl-Meyer AR, Ja asko L, Leyman I, et al. The poststroke hemiplegic patient. A method for evaluation of physical performance. Scand J Rehabil Med. 1975;7(1):13-31.

9. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res.1981; 4(4):483-92.

10. John J. Grading of muscle power: comparison of MRC and analogue scales by physiotherapists. Medical Research Council. Int J Rehabil Res. 1984; 7(2):173-81.

11. Bohannon RW, Smith MB. Interrater rehabili-tyof a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7.

12. Kotov SV, Misikov VK, Kovalenko AP, et al. Atlas ul'trazvukovoi vizualizatsii myshts dlya botu-linoterapii. Verkhnyaya konechnost'. Metodicheskoe rukovodstvo [Atlas of ultrasound imaging of muscles for botulinum therapy. Upper limb. Methodological guidance]. Moscow: Libright; 2015.

13. Sarzynska-Dlugosz I, Szczepannska-Szerej A, Druzdz A, et al. Real-world effectiveness of abobotulinumtoxinA (Dysport®) in adults with upper limb spasticity in routine clinical practice: an observational study. Neurol Neurochir Pol. 2020; 54(1):90-99. doi: 10.5603/PJNNS.a2020.0004. Epub 2020 Jan 20.

14. Li-Chun S, Rong C, Chuan F, et al. Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int. 2019 Apr 7;2019:8329306. doi: 10.1155/2019/8329306. eCollection 2019.

15. Artemyev DV, Orlova OR, Morenkova AZ. Use of Botox in medical practice. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2000;(4):46-51. (In Russ.).

16. Kadykov AS, Shakhparonova NV. Spasticity as a problem of motor rehabilitation: the role of miorelaxants. Consilium Medicum. Nevrologiya i revmatologiya. 2014;(1):56-9. (In Russ.).

17. Sitnova MA, Esin OR, Esin RG. Post-stroke shoulder pain: pathogenesis, treatment principles. Prakticheskaya meditsina. 2014; (2):53-7. (In Russ.).

18. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum toxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 6;70(19):1691-8. doi: 10.1212/01.wnl.0000311391.00944.c4.

19. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spastici-ty.J Neural Transm (Vienna). 2008;115(4):617-23. doi: 10.1007/s00702-007-0869-3. Epub 2008 Mar 6.

20. Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.

21. Khasanova DR, Agafonova NV. Botulinotherapy in early post-stroke spasticity hands. Klinicheskaya gerontologiya. 2012;18(11-12):25-31. (In Russ.).

22. Khat'kova SE. Current trends in the use of botulinum treatment in post-stroke spasticity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112(8):92-9. (In Russ.).


For citation:


Lutsik V.N., Slyunkova E.V., Kotov S.V., Misikov V.K., Biryukova E.V. Arm spasticity after stroke: botulinum toxin therapy in combination with multimodal stimulation. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):19-23. (In Russ.) https://doi.org/10.14412/2074-2711-2020-3-19-23

Views: 38


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)